These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8226435)

  • 1. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination.
    Goetz MB; Sayers J
    J Antimicrob Chemother; 1993 Aug; 32(2):325-34. PubMed ID: 8226435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrotoxicity of vancomycin, alone and with an aminoglycoside.
    Rybak MJ; Albrecht LM; Boike SC; Chandrasekar PH
    J Antimicrob Chemother; 1990 Apr; 25(4):679-87. PubMed ID: 2351627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy.
    Nahata MC
    Chemotherapy; 1987; 33(4):302-4. PubMed ID: 3608631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity.
    Smith CR; Lipsky JJ; Lietman PS
    Antimicrob Agents Chemother; 1979 Jun; 15(6):780-2. PubMed ID: 475363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vancomycin/aminoglycoside nephrotoxicity.
    Dean RP; Wagner DJ; Tolpin MD
    J Pediatr; 1985 May; 106(5):861-2. PubMed ID: 3998936
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.
    Cano EL; Haque NZ; Welch VL; Cely CM; Peyrani P; Scerpella EG; Ford KD; Zervos MJ; Ramirez JA; Kett DH;
    Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy.
    Pauly DJ; Musa DM; Lestico MR; Lindstrom MJ; Hetsko CM
    Pharmacotherapy; 1990; 10(6):378-82. PubMed ID: 2287556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient.
    Vance-Bryan K; Rotschafer JC; Gilliland SS; Rodvold KA; Fitzgerald CM; Guay DR
    J Antimicrob Chemother; 1994 Apr; 33(4):811-21. PubMed ID: 8056700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in aminoglycoside induced nephrotoxicity: a prospective, hospital-based study.
    Sweileh WM
    Curr Clin Pharmacol; 2009 Sep; 4(3):229-32. PubMed ID: 19500072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.
    Cimino MA; Rotstein C; Slaughter RL; Emrich LJ
    Am J Med; 1987 Dec; 83(6):1091-7. PubMed ID: 3503577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older.
    Wang Y; Dai N; Wei W; Jiang C
    Clin Interv Aging; 2021; 16():1023-1035. PubMed ID: 34103905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxicity induced by gentamicin and amikacin.
    Smith CR; Maxwell RR; Edwards CQ; Rogers JF; Lietman PS
    Johns Hopkins Med J; 1978 Mar; 142(3):85-90. PubMed ID: 342789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function.
    Sweileh WM
    Fundam Clin Pharmacol; 2009 Aug; 23(4):515-20. PubMed ID: 19709328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of aminoglycoside serum assays on clinical decisions and renal toxicity.
    Arroyo JC; Milligan WL; Davis J; Mitchell D
    South Med J; 1986 Mar; 79(3):272-6. PubMed ID: 3513326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients.
    Chuma M; Makishima M; Imai T; Tochikura N; Suzuki S; Kuwana T; Sawada N; Komatsu T; Sakaue T; Kikuchi N; Yoshida Y; Kinoshita K
    Ther Drug Monit; 2018 Feb; 40(1):109-114. PubMed ID: 29095798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between vancomycin-associated nephrotoxicity and the number of combined nephrotoxic agents.
    Ueki T; Sanematsu E; Furuya Y; Shinohara Y; Murakami Y; Miyazaki A; Sakamoto Y; Nakashima MN; Nakashima M
    Pharmazie; 2020 Jun; 75(6):279-283. PubMed ID: 32539926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and predictors of vancomycin-associated nephrotoxicity.
    Moh'd H; Kheir F; Kong L; Du P; Farag H; Mohamad A; Zurlo JJ
    South Med J; 2014 Jun; 107(6):383-8. PubMed ID: 24945176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amikacin nephrotoxicity in patients with chronic liver disease.
    Cortés J; Gamba G; Contreras A; Peña JC
    Rev Invest Clin; 1990; 42(2):93-8. PubMed ID: 2267454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating Renal Stress Using Pharmacokinetic Urinary Biomarker Data in Critically Ill Patients Receiving Vancomycin and/or Piperacillin-Tazobactam: A Secondary Analysis of the Multicenter Sapphire Study.
    Kane-Gill SL; Ostermann M; Shi J; Joyce EL; Kellum JA
    Drug Saf; 2019 Oct; 42(10):1149-1155. PubMed ID: 31240688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.
    Krcméry V; Fuchsberger P; Gocár M; Salát T; Bodnárová J; Sobota R; Koza I; Svec J
    Chemotherapy; 1991; 37(4):287-91. PubMed ID: 1790727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.